Paper Details

  1. Home
  2. Paper Details

Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.

Author: ButlerKathleen, GottliebAlice B, GrimesPearl, HamzaviIltefat, HarrisJohn E, HowellMichael D, JiTao, KuoFiona, LebwohlMark, PandyaAmit G, RosmarinDavid, SunKang

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study explored the use of ruxolitinib cream as a treatment for vitiligo, a condition causing skin discoloration. While there's no approved cure for vitiligo, current treatments are limited. The study investigated the effectiveness and safety of this cream for restoring skin color over a 52-week period.
Paper Details　
Original Abstract of the Article :
Vitiligo is a chronic autoimmune disease resulting in skin depigmentation and reduced quality of life. There is no approved treatment for vitiligo repigmentation and current off-label therapies have limited efficacy, emphasising the need for improved treatment options. We investigated the therapeuti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(20)30609-7

データ提供：米国国立医学図書館（NLM）

Investigating Ruxolitinib Cream for Vitiligo Treatment

[Vitiligo], a chronic autoimmune disease that causes [skin depigmentation], can significantly impact [quality of life]. While [current therapies] offer limited efficacy, this study explores the potential of [ruxolitinib cream] as a [novel treatment option] for vitiligo. Through a [randomized, controlled, phase 2 trial], the researchers investigated the [efficacy and safety] of ruxolitinib cream in patients with vitiligo. Their findings offer promising insights into the [therapeutic potential] of this cream for [re-pigmentation and improving quality of life] in vitiligo patients.

Ruxolitinib Cream: A Potential Breakthrough in Vitiligo Treatment

The study's results provide a glimmer of hope for patients with vitiligo, suggesting that [ruxolitinib cream] may offer a [more effective and safe] treatment option compared to [current therapies]. This could lead to [improved re-pigmentation and better quality of life] for individuals affected by this chronic condition.

The Future of Vitiligo Treatment: Exploring New Avenues

This study underscores the importance of [continuously exploring new treatment options] for [chronic conditions like vitiligo]. The development of [ruxolitinib cream] represents a significant step towards [improving treatment outcomes and enhancing the lives] of patients with vitiligo.

Dr.Camel's Conclusion

Just as a camel adapts to the changing desert landscape, researchers are constantly searching for new ways to treat vitiligo. This study offers a beacon of hope, suggesting that ruxolitinib cream may provide a more effective and safe treatment option for this challenging condition. By embracing innovation, we can empower individuals with vitiligo to live fulfilling lives, free from the limitations imposed by this chronic disease.

Date :
  1. Date Completed 2020-08-11
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

32653055

DOI: Digital Object Identifier

10.1016/S0140-6736(20)30609-7

Related Literature

Article Analysis
・Effective treatment of vitiligo
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.